Organon & Co. Income Taxes Paid
Organon & Co. (OGN) reported Income Taxes Paid of $293.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaid · last filed 2026-02-24
- Organon & Co. income taxes paid for the quarter ending 2021-12-31 was $113.00M.
- Organon & Co. income taxes paid for the quarter ending 2021-09-30 was $18.00M.
- Organon & Co. income taxes paid for the quarter ending 2021-06-30 was $18.00M.
- Organon & Co. income taxes paid for the quarter ending 2021-03-31 was $18.00M.
- Organon & Co. income taxes paid for fiscal 2024 was $293.00M, a 117.04% increase from fiscal 2023.
- Organon & Co. income taxes paid for fiscal 2023 was $135.00M, a 36.92% decline from fiscal 2022.
- Organon & Co. income taxes paid for fiscal 2022 was $214.00M, a 63.36% increase from fiscal 2021.
- Organon & Co. income taxes paid for fiscal 2021 was $131.00M.
| Period end | Income Taxes Paid 3 month | Income Taxes Paid 6 month | Income Taxes Paid 9 month | Income Taxes Paid 12 month |
|---|---|---|---|---|
| 2024-12-31 | $293.00M 10-K · filed 2026-02-24 | |||
| 2023-12-31 | $135.00M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $214.00M 10-K/A · filed 2025-11-10 | |||
| 2021-12-31 | $113.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $131.00M derived: sum of 2 quarters · filed 2024-02-26 | $149.00M derived: sum of 3 quarters · filed 2024-02-26 | $131.00M 10-K · filed 2024-02-26 |
| 2021-09-30 | $18.00M 10-Q · filed 2022-11-04 | $36.00M derived: sum of 2 quarters · filed 2022-11-04 | $18.00M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $18.00M 10-Q · filed 2022-08-05 | $18.00M 10-Q · filed 2021-08-16 | ||
| 2021-03-31 | $18.00M 10-Q · filed 2022-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |